More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/(+)-Etomoxir . Na [828934-41-4]
Chemical Structure
Chemical Structure
Chemical Structure

(+)-Etomoxir . Na [828934-41-4]

Research Use Only
AG-CR1-3688
AdipoGen Life Sciences
CAS Number828934-41-4
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight297.8 . 23.0
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    (+)-Etomoxir sodium salt [828934-41-4]
  • Delivery Days Customer
    10
  • ADR Class
    6.1
  • CAS Number
    828934-41-4
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Danger,Excepted quantity
  • Molecular Formula
    C15H18ClO4 . Na
  • Molecular Weight
    297.8 . 23.0
  • Scientific Description
    Chemical. CAS: 828934-41-4. Formula: C15H18ClO4 . Na. MW: 297.8 . 23.0. . Irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1a) a mitochondrial enzyme involved in fatty acid beta-oxidation. CPR-1a on the outer face of the inner mitochondrial membrane, consequently prevents the formation of acyl carnitines, a step that is necessary for the transport of fatty acyl chains from the cytosol into the intermembrane space of the mitochondria, essential for the production of ATP from fatty acid oxidation. Fatty acid beta-oxidation (FAO) inhibitor. By regulating fatty acid oxidation it has hypoketonaemic, hypocholesteraemic and hypolipogenic effect, and the potential to affect ketogenesis, cholesterol synthesis and gluconeogenesis. Useful agent for immunometabolism research. Anticancer, antiobesity and antidiabetes agent. Increases food intake and reduces hepatic ATP/ADP ratio. Mitochondrial fatty acid oxidation may provide NADPH for defense against oxidative stress and prevent ATP loss and cell death. PPARalpha activator/agonist. Shows non-specific effects on oxidative metabolism and cellular redox and induces acute production of ROS with associated evidence of severe oxidative stress in proliferating T cells at above 5microM concentration. Shown to have potentiating effects on chemotherapeutics agents. - Irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1a) a mitochondrial enzyme involved in fatty acid beta-oxidation. CPR-1a on the outer face of the inner mitochondrial membrane, consequently prevents the formation of acyl carnitines, a step that is necessary for the transport of fatty acyl chains from the cytosol into the intermembrane space of the mitochondria, essential for the production of ATP from fatty acid oxidation. Fatty acid beta-oxidation (FAO) inhibitor. By regulating fatty acid oxidation it has hypoketonaemic, hypocholesteraemic and hypolipogenic effect, and the potential to affect ketogenesis, cholesterol synthesis and gluconeogenesis. Useful agent for immunometabolism research. Anticancer, antiobesity and antidiabetes agent. Increases food intake and reduces hepatic ATP/ADP ratio. Mitochondrial fatty acid oxidation may provide NADPH for defense against oxidative stress and prevent ATP loss and cell death. PPARalpha activator/agonist. Shows non-specific effects on oxidative metabolism and cellular redox and induces acute production of ROS with associated evidence of severe oxidative stress in proliferating T cells at above 5microM concentration. Shown to have potentiating effects on chemotherapeutic agents.
  • SMILES
    O=C([C@@]1(CCCCCCOC2=CC=C(Cl)C=C2)CO1)[O-].[Na+]
  • Storage Instruction
    -20°C,2°C to 8°C
  • UN Number
    2811
  • UNSPSC
    12352200

References

  • Glucose kinetics during acute and chronic treatment of rats with 2[6(4-chloro-phenoxy)hexyl]oxirane-2-carboxylate, etomoxir: Y.T. Kruszynska & H.S. Sherratt; Biochem. Pharmacol. 36, 3917 (1987)
  • Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine: G.D. Lopaschuk, et al.; Circ. Res. 63, 1036 (1988)
  • Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus: K. Ratheiser, et al.; Metabolism 40, 1185 (1991)
  • The effect of etomoxir on the mRNA levels of enzymes involved in ketogenesis and cholesterogenesis in rat liver: G. Asins, et al.; Biochem. Pharmacol. 47, 1373 (1994)
  • Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir: F.J. Schmitz, et al.; Horm. Metab. Res. 27, 515 (1995)
  • Etomoxir, sodium 2-[6-(4-chlorophenoxy)hexyl] oxirane-2-carboxylate, inhibits triacylglycerol depletion in hepatocytes and lipolysis in adipocytes: T.D. Spurway, et al.; FEBS Lett. 404, 111 (1997)
  • Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure: D. Portilla, et al.; Am. J. Physiol. Renal. Physiol. 278, F667 (2000)
  • Etomoxir-induced increase in UCP3 supports a role of uncoupling protein 3 as a mitochondrial fatty acid anion exporter: P. Schrauwen, et al.; FASEB J. 16, 1688 (2002)
  • Etomoxir, a fatty acid oxidation inhibitor, increases food intake and reduces hepatic energy status in rats: C.C. Horn, et al.; Physiol. Behav. 81, 157 (2004)
  • Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir: E. Hernlund, et al.; Int. J. Cancer 123, 476 (2008)